Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Pentobarbital sodium
Le Vet BV
QN51AA01
Pentobarbital sodium
400 milligram(s)/millilitre
Solution for injection
POM: Prescription Only Medicine as defined in relevant national legislation
Cats, Cattle, Dogs, Goats, Horses, Mink, Rabbits, Rodents, Sheep
pentobarbital
Neurological Preparations
Authorised
2011-12-16
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Euthasol vet. 400 mg/ml, solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Per ml: ACTIVE SUBSTANCE: Pentobarbital sodium 400 mg (equivalent to pentobarbital 364.6 mg) EXCIPIENT(S): Benzyl alcohol (E1519) 20 mg Patent Blue V (E131) 0.01 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. Clear blue liquid. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs, cats, rodents, rabbits, cattle, sheep, goats, horses and mink. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Euthanasia 4.3 CONTRAINDICATIONS DO NOT USE for anaesthesia. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _0_ _7_ _/_ _1_ _2_ _/_ _2_ _0_ _1_ _6_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _5_ _1_ _4_ _1_ _p_ _a_ _g_ _e_ _ _ _n_ _u_ _m_ _b_ _e_ _r_ _:_ _ _ _1_ 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES - Intravenous injection of pentobarbital has the ability to cause induction excitement in several species of animal and adequate sedation should be applied if deemed necessary by the veterinary surgeon. Measures should be taken to avoid perivascular administration (e.g. by using intravenous catheter). - The intraperitoneal route of administration may cause a prolonged onset of action with an increased risk of induction excitement. Intraperitoneal administration must only be used following appropriate sedation. Measures should be taken to avoid administration into the spleen or organs/tissue Read the complete document